Literature DB >> 30357751

Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.

Mark Plander1, Tamás Szendrei2, Árpád Vadvári3, János Iványi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30357751     DOI： 10.1007/s12253-018-0482-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


× No keyword cloud information.
  7 in total

1.  Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.

Authors:  Sophie Bernard; Lauriane Goldwirt; Sandy Amorim; Pauline Brice; Josette Brière; Eric de Kerviler; Samia Mourah; Hélène Sauvageon; Catherine Thieblemont
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

2.  Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.

Authors:  Aurélie Cabannes-Hamy; Richard Lemal; Lauriane Goldwirt; Stéphanie Poulain; Sandy Amorim; Renan Pérignon; Juliette Berger; Pauline Brice; Eric De Kerviler; Jacques-Olivier Bay; Helene Sauvageon; Kheira Beldjord; Samia Mourah; Olivier Tournilhac; Catherine Thieblemont
Journal:  Am J Hematol       Date:  2016-03       Impact factor: 10.047

3.  Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.

Authors:  Christopher Mason; Steven Savona; Josephine N Rini; Jorge J Castillo; Lian Xu; Zachary R Hunter; Steven P Treon; Steven L Allen
Journal:  Br J Haematol       Date:  2016-07-13       Impact factor: 6.998

4.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

5.  Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome.

Authors:  Laurys Boudin; Matthieu Patient; Emilie Roméo; Jean-Sébastien Bladé; Jean-Pierre de Jauréguiberry
Journal:  Leuk Lymphoma       Date:  2018-03-23

6.  Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

Authors:  Jorge J Castillo; Shirley D'Sa; Michael P Lunn; Monique C Minnema; Alessandra Tedeschi; Frederick Lansigan; M Lia Palomba; Marzia Varettoni; Ramon Garcia-Sanz; Lakshmi Nayak; Eudocia Q Lee; Mikael L Rinne; Andrew D Norden; Irene M Ghobrial; Steven P Treon
Journal:  Br J Haematol       Date:  2015-12-21       Impact factor: 6.998

Review 7.  Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

Authors:  Laurence Simon; Aikaterini Fitsiori; Richard Lemal; Jehan Dupuis; Benjamin Carpentier; Laurys Boudin; Anne Corby; Thérèse Aurran-Schleinitz; Lauris Gastaud; Alexis Talbot; Stéphane Leprêtre; Béatrice Mahe; Camille Payet; Carole Soussain; Charlotte Bonnet; Laure Vincent; Séverine Lissandre; Raoul Herbrecht; Stéphane Kremer; Véronique Leblond; Luc-Matthieu Fornecker
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941
  7 in total
  2 in total

1.  Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case report.

Authors:  Maria Gavriatopoulou; Ioannis Ntanasis-Stathopoulos; Lia-Angela Moulopoulos; Alexandros Manaios; Despina Fotiou; Evangelos Eleutherakis-Papaiakovou; Magdalini Migkou; Charis Bourgioti; Evangelos Terpos; Efstathios Kastritis; Meletios-Athanasios Dimopoulos
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 2.  Rare central nervous system lymphomas.

Authors:  Furqaan Ahmed Kaji; Nicolás Martinez-Calle; Vishakha Sovani; Christopher Paul Fox
Journal:  Br J Haematol       Date:  2022-03-16       Impact factor: 8.615
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.